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CONNOR JADE JOCELYN GRAHAM. A small molecule screen to identify a
potential treatment for MTDPS3. (Under the direction of STEPHEN DUNCAN).
ABSTRACT
Mitochondrial DNA Depletion Syndrome 3 (MTDPS3) is the most common
mitochondrial DNA (mtDNA) depletion syndrome. MTDPS3 is an autosomal
recessive disorder caused by a mutation in the deoxyguanosine kinase (DGUOK)
gene in which a reduction in mtDNA nucleotides results in decreased levels of
Adenosine Triphosphate (ATP). The DGUOK phenotypes vary; however, liver
dysfunction tends to be consistent for all pediatric patients. Liver transplants can
be beneficial; however, it’s only a palliative treatment at best, and the affected
population rarely reaches adulthood. This thesis describes a high-throughput
drug screen to identify a potential therapy for MTDPS3. MTDPS3 mutant
hepatocytes derived from induced pluripotent stem cells (iPSCs) were utilized in
the drug screen of the South Carolina Compound Collection (SC3) library. From
the primary screen of 10,000 compounds, 63 compounds increased ATP levels at
a sample number of one. The primary hits were used to perform biological
replicates with the knockout cells, and six can increase ATP levels consistently.
Two of the six compounds increased ATP production at eight different drug
concentrations. My results show six small molecules with the therapeutic
potential to treat an MTDPS3 phenotype in-vitro.
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CHAPTER 1: INTRODUCTION
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Mitochondrial Biology
The complexity of mitochondrial biology begins with the theory of
endosymbiosis (Martin & Mentel, 2010). Once believed to be an independent
free-roaming cell, the mitochondria created a mutualistic relationship with a
larger prokaryotic cell (Martin & Mentel, 2010). Millions of years later, the
doubled membraned organelle produces Adenosine Triphosphate (ATP) for every
cell in the human body (Figure 1). The mitochondria are the only organelle that
contains DNA, known as the mitogenome. Unlike nuclear DNA, however, mtDNA
is circular and haploid. Instead of being inside a nucleus, mtDNA is in a nucleoid
anchored to the mitochondria's inner membrane (Almannai, El-Hattab, &
Scaglia, 2018). There are 37 genes in the mitogenome, and 13 of them encode the
Electron Transport Chain (ETC) complexes, while the remainder codes for
mtDNA replication machinery. THE ETC consists of five complexes embedded in
the inner mitochondrial membrane (Cooper, 2000) (Figure 2). The ETC is one of
two primary components of oxidative phosphorylation (OXPHOS). Together with
the mechanism of chemiosmosis, the ETC produces ATP.
Oxidative Phosphorylation
OXPHOS is the mechanism that produces the majority of ATP in a cell,
with the help of glycolysis and the citric acid cycle (CAC) (Cooper, 2000). The
first molecule, NADH, is relieved of two electrons which enter Complex I of the
ETC to begin the process. The negative subatomic particles pass through
Coenzyme Q (CoQ), also known as ubiquinone. The second molecule produced by
the CAC cycle, FADH2, also releases electrons that flow through Complex II and
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CoQ. The electrons leave ubiquinone and enter Complex III and Cytochrome C.
Finally, the electrons are passed through Complex IV (cytochrome oxidase),
where they bond to the hydrogen + ions in the mitochondrial matrix O2 to form
two water molecules. This entire process is known as the ETC. Naturally
occurring hydrogen + ions in the mitochondrial matrix are pumped across the
membrane and into the intermembrane space throughout the electron transfer
process. Consequently, creating a proton gradient, with an accumulation of
hydrogen + ions in the intermembrane space. This gradient fuels ETC complex V
(ATP synthase) by going from a high-energy state to a lower one. This
equilibrium process creates a conversion where a phosphate group is attached to
each adenosine diphosphate (ADP), creating the final ATP product. Therefore,
the primary responsibility of the mitogenome is to produce energy for cellular
activities.
Mitochondrial DNA Depletion Syndromes
Despite having DNA, the mitochondria still depends on nuclear DNA to
help with replication and maintenance (Bogenhagen, 2012) (Figure 3). The
replication process is uninterrupted, requires copious proteins, a constant supply
of nucleotides, and is independent of cell division (Almannai, El-Hattab, &
Scaglia, 2018). Defects in the nuclear genes causes abnormal mtDNA
maintenance (Table 1). These defects create depletions and deletions in mtDNA,
and those disorders are known as Mitochondrial DNA Depletion Syndromes
(MTDPSs). MTDPSs are diseases caused by disruptions in mtDNA’s function and
maintenance and manifests as various multi-organ system malfunctions
(Shimura, et al., 2020; Almannai, El-Hattab, & Scaglia, 2018) (Table 1).
11

DGUOK Deficiency
Mitochondrial DNA Depletion Syndrome 3 (MTDPS3), an autosomal
recessive disorder, accounts for one-fourth of all MTDPSs (Sezer, Ozçay, Balci, &
Alehan, 2015). MTDPS3 is caused by the nuclear gene deoxyguanosine kinase
(DGUOK) mutation. The transcription and translation of the DGUOK gene
produce the protein that travels to the mitochondria to assist in mtDNA
replication (Van Goethem, Dermaut, Löfgren, Martin, & Van Broeckhoven, 2001;
Sarzi, et al., 2007). Specifically, the DGUOK protein phosphorylates mtDNA
nucleosides, deoxyadenosine monophosphate (dAMP), and deoxyguanosine
monophosphate (dGMP) (Gower, Carr, & Ives, 1979) (Figure 4). The nucleotides
are the building blocks for mtDNA needed to produce ATP. Without mtDNA, the
human cell will lose its primary energy source, leading to apoptosis or necrosis
(Tsujimoto, 1997). A mutated DGUOK protein causes a depletion in mtDNA,
which ultimately leads to a depletion in ATP (Figure 4).
The most well-known cases of MTDPS3 involve infants suffering from hepatic
failure. This disease is known for its hepatocerebral dysfunction in most patients
due to the accompanying neurological aberrations. This disease was first
characterized in the late twenty-century when a 9-month-old infant died of liver
failure (Boustany, Aprille, Halperin, Levy, & DeLong, 1983).
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Figure 1. Mitochondrion Structure
A mitochondrion is a double-membraned organelle that contains a genome and
produces most energy in a cell. (Created using Biorender.)
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Figure 2. Oxidative Phosphorylation.
Oxidative phosphorylation(OXPHOS) produces approximately 24-32 ATP
molecules per one molecule of glucose. This process consists of the electron
transport chain (ETC) and chemiosmosis. (Created using Biorender.)
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Table 1. mtDNA maintenance defects

(Almannai, El-Hattab, & Scaglia, 2018) Defects in nuclear genes that maintain
and help replicate mtDNA lead to depletions in mtDNA and ultimately multiorgan system failure.
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Figure 3. mtDNA replication proteins
(Almannai, El-Hattab, & Scaglia, 2018). Above are the proteins associated with
mtDNA replication. The functions of the proteins are in Table 1.
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Figure 4. Consequence of DGUOK protein.
(A). The DGUOK protein enters the mitochondria through an intermembrane
channel. It phosphorylates purine deoxyribonucleosides. Deoxyribonucleotides
(dNTPs) are the foundation of mtDNA. (B). The implications of a DGUOK
mutation which results in a depletion in ATP.
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The symptoms vary per patient but include the two mentioned above as well as
hypoglycemia and increased lactate accumulation (Mandel, et al., 2001; Salviati,
et al., 2002; Mancuso, et al., 2005; Dimmock, et al., 2008; Jing, et al., 2018). The
most common current therapy is a liver transplant; however, due to the onset of
declined brain functions and low survival rate, this option is palliative at best
(Dimmock, et al., 2008; Jing, et al., 2018).
Disease Modeling and Therapy with iPSCs and Drug Screens
Induced pluripotent stem cells (iPSCs), reprogrammed somatic cells, are
becoming the leading tool in modeling diseases for therapeutic applications (SiTayeb, et al., 2010). The benefit of iPSCs is their ability to become almost any cell
type. Discovered by Dr. Yamanaka in 2006, these revolutionary stem cells have
changed the way we study and treat diseases. Somatic cells are reprogrammed
when introduced to Yamanaka factors (OCT4, SOX2, NANOG, or LIN28 and
KLF4 or MYC) (Bellin, Marchetto, Gage, & Mummery, 2012). An essential
transcription factor for this induction is Oct4, which indicates pluripotency (Liu,
David, Trawczynski, & Fessler, 2020). Transcription factors help turn genes “on”
and “off.” In this case, the Yamanaka factors manipulate the genes in the somatic
cells to induce pluripotency. The idea of iPSCs arose due to the challenges of
using embryonic stem cells (ESCs) for clinical application.
Human ESCs were created in the later 20th century with the hope of using
cell therapies in numerous human ailments and injuries (Yamanaka, 2020).
ESCs are pluripotent stem cells from a human embryo, and similarly to iPSCs;
they can differentiate into all three germ layers (Evans & Kaufman, 1981) (Figure
4 and 5). Utilizing ESCs became problematic during the early 2000s due to
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ethical issues using human embryos (Yamanaka, 2020). The production of new
cell lines even became a national political issue polarizing the country between
medical advancement and principled beliefs. The problem of tissue rejection was
also a challenge for cell-based therapies using ESCs. Consequently, the idea of
using patients’ somatic cells to generate differentiating stem cells came to be. The
advantages of using iPSCs include proliferation potential, controlling genomic
variants, and autologous transplantation (Yamanaka, 2020). Although relatively
new, iPSC technology can recapitulate various diseases, fortifying their role in
clinical studies (Elitt, Barbar, & Tesar, 2018). With other therapeutic techniques
such as high throughput drug screens and gene editing, iPSCs have become the
leading disease modeling tool.
An iPSC-based drug screen requires four stipulations: assay development,
primary screen, secondary screening, and ultimately in vivo testing (Elitt, Barbar,
& Tesar, 2018). Assay development involves creating or following a robust
differentiation protocol with the iPSCs recapitulating the disease of study's
phenotype (Elitt, Barbar, & Tesar, 2018). For the primary screening finding a
screening library that meets the project's needs is imperative. Identifying the
screening dose, controls, and eventual hit selection criteria is also important for
this second stage (Elitt, Barbar, & Tesar, 2018). The secondary screening requires
validating the hit compounds from the primary screen by performing biological
replicates and a dose-response assay (Elitt, Barbar, & Tesar, 2018). The final
component of an iPSC-based drug screen demonstrates the efficacy and toxicity
of the compounds in live animal models (Elitt, Barbar, & Tesar, 2018). Along with
comprehending the steps of a high throughput drug screen, defining what type of
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screen will be executed is also essential. When performing a phenotypic screen,
the objective is to identify chemical compounds that modify the cell's phenotype
(Moffat, Vincent, Lee, Eder, & Prunotto, 2017). Unlike a target-based screen, no
defined molecular target allows for a larger target space (Henry & Wlodkowic,
2019) (Figure 7). While target-based drug discovery (TDD) has been the standard
approach in this space for 30 years, phenotypic drug discovery (PDD) screens
provide illuminating awareness in unpredicted consequences of compounds and
the ways they alter a cell's phenotype (Moffat, Vincent, Lee, Eder, & Prunotto,
2017).
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Figure 5. Embryonic Stem Cell Differentiation
ESCs are the inner mass of an embryonic blastocyst, and they can become every
cell type depending on the cellular microenvironment. (Created using Biorender.)
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Figure 6. Induced Pluripotent Stem Cell Differentiation
iPSCs are somatic cells that were treated with specific transcription factors. They
can become every cell type except a germ cell. (Created using Biorender.)
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Figure 7. Target-Based vs. Phenotype-Based Screens
(Henry & Wlodkowic, 2019) (A). Target-based drug discovery (TDD) involves
screening for compounds interacting with a specific target. (B). Phenotypic drug
discovery (PDD) allows a broader target margin while also providing insight into
the diverse effects of specific compounds.
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Drug Screen using DGUOK -/- iPSCs-derived hepatocytes
The Duncan lab previously published article an iPSC-based phenotypic
drug screen designed to identify a treatment for MTDPS3 (Jing, et al., 2018).
Following a previously published protocol (Si-Tayeb, et al., 2010), the stem cells
were differentiated, and their mitochondrial respiration was measured. This
experiment was to ensure that the differentiated cells could model mitochondrial
function. This protocol concluded that the hepatogenesis did not disturb the
natural metabolic progression in the cells. Later, an MTDPS3 model was
generated utilizing CRISPR/Cas9 to manipulate the DGUOK exon 4. The selected
exon resembles patients having similar deletions in this location (Jing, et al.,
2018). The cell line contained frameshift deletions of 14 and 5 bp and successfully
differentiated into hepatocytes (Figure 8). MTDPS3 patient cells tend to have
severe and specific mitochondrial dysfunction, including depletions in mtDNA,
ATP production, ETC protein expression, membrane potential, and overall
oxygen consumption rate. These phenotypic qualities produced an MTDPS3
phenotype in an iPSC differentiated hepatocyte-like cell (Jing, et al., 2018).
In this previously published article, with a functional DGUOK -/- iPSC cell
line, a small molecule screen was performed using the SPECTRUM library. The
SPECTRUM library consists of 2,400 repurposed compounds that have been
previously tested and approved to treat humans (Jing, et al., 2018). Using a
luciferase assay to measure ATP production, 34 primary hits were identified, with
15 of them producing at least 20% more energy than the control cells (Figure 10).
This experiment utilized the z-factor, a statistical test known for its aptness in
high throughput screens (Zhang, Chung, & Oldenburg, 1999). Out of the 15
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compounds, one increased ATP levels and ETC genes' expression, nicotinamide
adenine dinucleotide (NAD). NAD restores ATP production by activating
peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC1-α)
through deacetylation by Sirtuin 1 (Sirt 1). NAD increased gene expression of
several mitochondrial transcription factors (Jing, et al., 2018). Another
compound that increased ATP levels in the DGUOK -/- cells was Trimipramine
Maleate (TM), which was used as a positive control for the later experiments in
this thesis. Ultimately to cure MTDPS3, it is necessary to increase mtDNA
content, which NAD could not do and ultimately had a similar response to
the DGUOK -/- cells not treated with NAD. Therefore, this drug is not an ideal
treatment for MTDPS3, but also because the mechanism of how it enters the cell
is still unknown, and its inconsistencies in the iPSC model system (Jing, et al.,
2018).
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A.

B.

C.

Figure 8. Generation of DGUOK -/- iPSC-derived hepatocytes
(Jing, et al., 2018) (A). A schematic of the knockout cell line that contained
frameshift deletions of 14 and 5bp in Exon 4 using CRISPR/Cas9. (B).
Immunoblot analysis of cell extracts from DGUOK +/+ vs. DGUOK Δ14/Δ5 (C).
Immunofluorescence showed that the DGUOK Δ14/Δ5 cells could differentiate to
hepatocyte-like cells.
HSP90: Heat Shock Protein: conserved chaperone protein. HNF4A: Hepatocyte Nuclear
Factor: hepatic differentiation regulator. Serum Albumin: Protein produced by the liver.
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A.

B.

D.

C.

G.

E.

F.
H.

Figure 9. Recapitulating MTDPS3 Phenotype
(Jing, et al., 2018) (A). In the DGUOK -/- hepatocyte-like cells, there was a
decrease in mtDNA content (B). disruption in mitochondrial morphology and
membrane potential, (C). depletion in ETC protein expression (D, E, F) decrease
in oxygen consumption rate (oxidative phosphorylation) (G). depletion in ATP
levels (H). and an increase in lactate production.
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A.

C.

B.

D.

Figure 10. Drug Screen using DGUOK -/- iPSC-derived hepatocytelike cells
(Jing, et al., 2018) (A). The approach to identifying drugs from the SPECTRUM
library. (B). Experimental overview to identify compounds. (C). The results of the
primary screen. The blue line indicates a z-score ≥ 3. (D). Relative ATP levels of
confirmed hits (p ≤ 0.05).
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Table 2. The 15 Compounds from the Spectrum Library that
increased ATP levels

The compounds increased ATP levels by greater than 20% compared to the
negative control. The red box highlights NAD, a drug that consistently increased
energy production in the DGUOK -/- iPSC-derived hepatocytes.
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Project Overview
Similarly to Jing, et al., 2018, an iPSC-based phenotypic high throughput drug
screen was performed. The South Carolina Compound Collection (SC3) library
was selected to complete this project. The hypothesis for this thesis was that
compounds from the SC3 screening library would restore ATP production in the
differentiated DGUOK -/- cell line. There are approximately 130,000 repurposed
chemically diverse compounds adapted and organized for the sole purpose of
drug screening. The entire collection, known as the master library, is broken into
two sub-libraries, the Representative Set (RS) and the Representatives Set Lite
(RSL). The RS set is 10,000 small molecules that are chemically representative of
the master library, and the RSL set is the first 1,000 compounds of the RS set. As
a proof of concept, the RSL set was tested first. The remainder of the RS set was
completed after confirming that small molecules from the SC3 library could be
used to drug treat DGUOK -/- iPSC-derived hepatocytes. Specific aim 1 was to
screen for compounds in the library that could increase energy levels in the
mutant iPSC-derived hepatocyte. Specific aim 2 confirmed the hit compounds
from the primary screen and identified the candidates that most effectively
improved mitochondrial function in the model cells.
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CHAPTER 2: MATERIALS AND METHODS
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Maintaining iPSCs
Materials
Non-treated P-1oo culture dishes (Corning) were prepared for iPSCs by
adding 5mL of prepared E-cad ((E-cadherin-Fc) (Nagaoka & Duncan, 2012)) to
the plates and storing it at 37 °C for one hour up. The E-cad was aspirated from
the dishes, and 2ul/ml of zbFGF to mTeSR1 (Ludwig, et al., 2006) was placed on
the p-100. iPSCs were passaged by adding 5mL of room temperature
Versene/EDTA (Gibco) to the passaged plate and placed in hypoxic conditions
(4%O2/5%CO2) at 37 °C for 4 minutes. After retrieving the p-100, the
Versene/EDTA (Gibco) was aspirated off. The cells were washed with 5ml of
warm 2ul/ml of zbFGF to mTeSR1 (Ludwig, et al., 2006), and then the aliquoted
cell suspension was placed a newly prepared p-100 with media. The dishes were
then placed in 4%O2/5%CO2 at 37 °C. The cells were maintained by removing
the media every day and feeding each p-100, new 2ul/ml of zbFGF to mTeSR1
(Ludwig, et al., 2006). Due to the rapid growth of the iPSCs, they were passaged
to new p-100s every time the dish was around 60-75% confluency, which usually
took 3-4 days to occur.
Plating for Cell Differentiation
Once the confluency of the dish was around 75-80%, the p-100s (Corning)
were ready for plating. The p-100 to 96-well plate ratio is 1:1. The sterile 96-well
plate (Corning) was prepared by adding 60uL of the Matrigel coating (Geltrex
and DMEM/F12, 2mg/ml, Invitrogen) to the plate placed at 37 °C. for 1 hour. The
media was aspirated off, and 2ml of Accutase (Stemcell Tech) was added to each

32

p-100. The dishes were then placed in hypoxic conditions (4%O2/5%CO2 at 37
°C) for 2 minutes. Once the p-100s were retrieved, they were washed with warm
2ul/ml of zbFGF to mTeSR1 (Ludwig, et al., 2006) to detach the cells. The cell
suspension was collected and centrifuged at 300RCF for 5 minutes in a
centrifuge-safe conical tube. After the centrifuge cycle, the media was aspirated,
which left the cell pellet untouched at the bottom. The pellet was resuspended
with 1ml + 2ul/ml of zbFGF to mTeSR1 (Ludwig, et al., 2006) per 96-well plate.
100ul of cell suspension was pipetted into the 96-well plate and stored in
4%O2/5%CO2 at 37 °C.
Hepatocyte Differentiation
On days 1-2, the recently plated 96-well plate was fed 95uL of RPM1 media
(Invitrogen) containing B27 - (20ul/ml, Invitrogen), FGF2 (20ng/ml,
Invitrogen), ActA (100ng/ml, R and D systems), and BMP-4 (10ng/ml, R and D
Systems) and stored at 37 °C in normoxic conditions (O2/5% CO2). On days 3-5,
the cells were fed 95uL of RPMI with B27 - (20ul/ml, Invitrogen) and ActA
(100ng/ml, R and D Systems) and stored back at O2/5% CO2 in 37 °C. On day 5,
due to the tendency to overgrow, causing cell death, the cells were treated with
60ul Versene/EDTA (Gibco) for 15 seconds before the RPMI media (Invitrogen)
was replaced gently. On days 6-10, the differentiating cells were fed 95uL of
RPMI media with B27 + (20ul/ml, Invitrogen), FGF2 (20ng/ml, Invitrogen), and
BMP-4 (20ng/ml, R and D Systems) and stored in hypoxic conditions
(4%O2/5%CO2) at 37 °C. On days 11-15, the cells were fed 95uL of RPMI media
(Invitrogen) with B27 + (20ul/ml, Invitrogen) and HGF (20ng/ml, Peprotech)
and stored in 4%O2/5%CO2 at 37 °C. On days 16-20, the last five days, the
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immature hepatocyte-like cells were fed 95uL of HCM media (Lonza) with OSM
(20ng/ml, R and D Systems) and stored in normoxic conditions (O2/5% CO2) at
37 °C.
South Carolina Compound Collection (SC3)
Dr. Charles Beam's donation of 3,000 chemical compounds founded the
South Carolina Compound Collection (SC3). Due to the continual contribution
from chemists everywhere, this library now contains over 130,000 diverse small
chemical molecules. The SC3 is MUSC's first proprietary screening library
maintained by Dr. Yuri Peterson (MUSC Drug Discovery Core). The library, as
mentioned before, was broken into two smaller libraries using a biochemical
algorithm that arranged them by chemical structure (Figure 12). The RS library
was utilized for this project, which are 10,000 compounds chemically
representative of the entire SC3 master library. All compounds and their
chemical properties can be found in a secure and highly organized database.
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Figure 11. The South Carolina Compound Collection Library
The master library consists of 130,000 chemically diverse small molecules. The
representative set (RS) is 10,000 compounds representing the entire master
library. The representative lite set (RSL) are the first 1,000 compounds of the RS
set.
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Drug Treatment
The 10,000 compounds, stored in the MUSC Drug Discovery Core, are
currently diluted in a DMSO solution, making their concentration 1mg/ml
(calculated by Dr. Yuri Peterson). The lab currently has diluted samples of the
compounds in sterile Hanks’s Balanced Salt Solution (HBSS) on 96-well plates
organized by their RS number and diluted to 100ug/ml, and this has been named
the master plate. From the master plate, the “working stock” plate was created so
that compounds could be easily accessed. The compounds in the working plate
were a 1/5th dilution in HBSS (20ug/ml concentration).
Primary Screen: From days 16-20, the DGUOK -/- iPSC-derived
hepatocytes were treated with the 5uL of the small molecules (RS library) and
95uL of HCM media with OSM, which created a final concentration of 1ug/ml
concentration. The negative control was 0.1% DMSO, and the positive control
was 5uM TM. To accurately measure ATP produced by aerobic respiration with
added compounds alone, glycolysis was inhibited by adding 20mM 2-deoxy-Dglucose (2DG) to the cells on the 20th day of feeding and drug treating for 24
hours (Figure 13).
Confirming Hits: The 63 compounds that increased ATP were used to treat day
16 DGUOK -/- hepatocyte-like cells at a concentration of 1ug/1ml with replicates
(N=8). The rest of the drug treating protocol followed what was mentioned above
in the primary screen.
Dose-Response: Six compounds were found to consistently increase ATP levels in
the DGUOK -/- iPSC-derived hepatocyte. Two of the six compounds were
selected to perform an 8-point dose-response assay. Utilizing a two-fold dilution,
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the concentrations ranged from 40uM to 0.3125uM. The cells were treated like
previously stated above on day 16 and for five days, treated with 2DG on day 20
for 24 hours. On day 21, a luciferase assay was performed to measure ATP
production.
Luciferase Assay
ATP production was measured on day 21 DGUOK -/- hepatocyte-like cells
using a CellTiter-Glo kit (Progema). The experiment was performed per the
manufacturer’s instructions. The CellTiter-Glo reagent was taken out of the
freezer and placed in a dark location for two hours. An hour and thirty minutes
later, the 96-well plates were removed from normoxic conditions (O2/5% CO2) at
37 °C. Once the reagent and plates were at room temperature, the cells were
washed with 60ul of Phosphate Buffer Saline (PBS) three times, leaving the third
wash on the cells. After the third wash, 60ul of reagent solution was added to the
plates. The 96-well plates were immediately covered in aluminum foil and placed
on a shaker for 20-30 minutes. The reagent will lyse and interact with the
endogenous ATP in the cells. 100ul of the now homogenous solution was
transferred to opaque-walled plates and read on a plate reader. This
bioluminescent assay works when the ATP in the cells interacts with the luciferin
in the CellTiter Glo-reagent. This reaction produces oxyluciferin and releases
energy (light) detected by a microplate reader.
Z-Score Analysis
The z-score is a standard statistic test, where the values are measured a
certain number of standard deviations away from the average mean of the data
set. For this project, compounds that could increase ATP levels in the DGUOK-/37

hepatocyte-derived cells with a z-score of 3 were selected. This means that at least
99% of the remaining compounds are not as significant and are "covered" within
three standard deviations of the mean. The z-scores were calculated using this
3(𝜎𝑆+ +𝜎𝐷𝑀𝑆𝑂 )

formula, = 1-

|𝜇𝑆−𝜇𝐷𝑀𝑆𝑂 |

, where 𝜎𝑆 and 𝜎𝐷𝑀𝑆𝑂 is the standard deviation of the

sample (S) and the DMSO control (DMSO) respectively and 𝜇𝑆 and 𝜇𝐷𝑀𝑆𝑂 is the
mean of the sample and DMSO.
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Experimental Overview
The RSL library was screened first, which is the first 1,000 compounds of
the RS library, as a proof of concept (Figure 14). Once the RSL was completed, we
moved on to the RS library. Due to the size of the library, we performed our
experiment with N=1. Since a reduction of ATP is one of MTDPS3’s side effects,
we decided to measure if the small molecules could increase ATP in the DGUOK /-

hepatocyte-like cells. The cells were differentiated in 96-well plates and treated

with compounds with a concentration of 1ug/1ml on day 16, for five days. On day
20 20mM 2-DG was added to inhibit glycolysis for one day. This was to prevent
the production of non-mitochondrial ATP (Jing, et al., 2018). ATP was measured
by following the directions of the ATP assay kit. This assay uses the enzyme
luciferase to lysis and react with endogenous ATP molecules in the cells to
produce a light emission that can be read on a plate reader. From this data, I
performed a z-factor analysis to identify primary hits (Figure 15). Out of 10,000
small molecules, 63 hit compounds had z-scores The RSL library was screened
first, which is the first 1,000 compounds of the RS library, as a proof of concept
(Figure 14). Once the RSL was completed, we moved on to the RS library. Due to
the size of the library, we performed our experiment with N=1. Since reducing
ATP is one of MTDPS3’s side effects, we decided to measure if the small
molecules could increase ATP in the DGUOK -/- hepatocyte-like cells. The cells
were differentiated in 96-well plates and treated with compounds with a 1ug/1ml
on day 16 for five days. On day 20, 20mM 2-DG was added to inhibit glycolysis
for one day. 2-DG was to prevent the production of non-mitochondrial ATP (Jing,
et al., 2018). ATP was measured by following the directions of the ATP assay kit.
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This assay uses the enzyme luciferase to lyse and react with endogenous ATP
molecules in the cells to produce a light emission that can be read on a plate
reader. A z-factor analysis was performed to identify primary hits (Figure 15). Out
of 10,000 small molecules, 63 hit compounds had z-scores ≥ 3.
Confirming Hits
Following a similar experiment to the primary screen, the 63 hits
compounds were tested with replicates, N=8. This experiment confirmed if the
compounds were naturally increasing ATP levels in the DGUOK -/- differentiated
cells. An analysis was performed to determine the validity of the 63 hits
compounds, along with a student’s t-test to determine significance between the
compounds and negative control, DMSO. The drugs needed to have a normalized
ratio average ≥ 1 and p-value of ≤ 0.05 to be considered for the final selection.
From the 63 compounds, six increased ATP levels at a 1ug/ml concentration
(Figure 16). The negative control was 0.1% DMSO, and the positive control was
5uM TM.
The Final Six
Out of 10,000 compounds, six consistently increased ATP levels in the
DGUOK -/- hepatocyte-like cells (Figure 16). All the compounds had z-scores
greater than or equal to 3, normalized ratio averages greater than or equal to 1,
and p-values less than or equal to 0.05 (Figure 17).
Dose-Response Assay
Following the final requirement of an iPSC-based drug screen, a doseresponse assay was performed to assess the compounds' maximal concentration
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effect and toxicity levels. (Elitt, Barbar, & Tesar, 2018). Due to time restrictions,
only two compounds were selected to be tested with an 8-point dose-response
assay. The concentrations ranged from 40uM and 0.3125uM with a two-fold
dilution. The first small molecule chosen was D-09311 due to the initial z-score of
the primary screen. The dose-response graph shows the expected sigmoidal curve
with increasing effects and increasing concentration (Figure 18). However,
around 4ouM, ATP production began to decline. This data could be the outcome
of drug toxicity; fewer cells make fewer ATP molecules. Regardless, it would be
best to explore more concentration levels, specifically higher than 40uM and
lower than 20uM.
The second compound, D-88920, was selected due to drug availability.
The dose-response graph showed that ATP production was increased around 50%
for all eight concentrations compared to the negative control, DMSO (Figure 19).
It could be assumed that this small molecule reached the maximum effect range
at the lowest concentration, 0.3125uM, if it followed the schematic of the doseresponse graph. It can also be concluded that this specific compound has a low
concentration range where ATP production is increasing. To further analyze this,
it would be wise to explore drug concentrations in the nanomolar range.
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Figure 12.Thesis Experimental Design
An overview of this thesis project. Using compounds from the SC3 library to
increase ATP production in DGUOK -/- iPSC-derived hepatocytes.
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Figure 13. RSL Z-Scores
As a proof of concept, 1,000 compounds of the RSL set were tested (N=1) to see if
they could increase ATP levels in the DGUOK -/- iPSC-derived hepatocytes. These
are the z-scores of the first 1,000 compounds of the RS set. The emission score
detected from the plate related were converted to Z-scores and normalized to the
negative control, DMSO. The black line indicates the cutoff at a z-score of 3. The
small molecules with negative z-scores were assumed to have killed the cells.
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Figure 14. Primary Screen of the SC3 Library
Day 16 DGUOK -/- iPSCs derived hepatocytes were treated with each compound
(N=1) at an average 2ug/ml concentration for five days. The result of the primary
screen is the z-scores of the 10,000 compounds from the SC3 library. The zscores were normalized to the negative control DMSO. The black line indicates
the cutoff at a z-score of 3.
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Figure 15. Confirming the hits of the Primary Screen
Biological replicates were performed with the 63 compounds (N=8) following the
same experimental design as the primary screen. Out of the 10,000 small
molecules, 63 successfully increased ATP levels compared to the negative control
(DMSO) (Z-scores ≥ 3). The black line indicates the cutoff at a ratio average
greater than one. The red bars indicate the compounds selected for moving
forward, ratio averages ≥ 1 and p ≤ 0.05
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Table 3. Final Six Compounds

These are the six small molecules that can increase ATP levels consistently.
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Figure 16. 8-Point Dose Response Assay, D-09311
(A). A dose-response schematic. (B). Compound D-09311 had an increasing effect
on ATP production with increasing drug concentration.

48

A.

Dose Response Assay, D-88920

B.

Normalized Ratio Averages (N=4)

2.5
2

1.5
1
0.5
0

Drug Concentrations
Figure 17. 8-point Dose Response Assay, D-88920
(A). A dose-response schematic. (B). Compound D-88920 reached the maximum
effect of ATP production with all drug concentrations.
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MTDPS3 is fatal to its patients, and a novel treatment is needed despite its
rarity. This thesis project aimed to use a high throughput drug screen to find said
treatment. Utilizing iPSCs that were differentiated into hepatocyte-like cells
containing the DGUOK mutation as models, the SC3 library’s RS sub-library was
narrowed down to six compounds. These six compounds D-89944, D-15082, D09311, D-89670, D-85610, and D-88920, increased ATP levels in the knockout
cells. This thesis is the first step in finding a treatment that can treat MTDPS3 invitro. Two out of the six compounds are similar in chemical structure, reassuring
us that they have similar activity in the differentiated cells. Since the RS set was
representative of 120,000 compounds, it was decided to find the structurally
related compounds of our candidate hits, and 148 small molecules were at least
60% percent similar to our final six. It would be interesting to see if these
molecules can increase ATP and affect this disease’s pathology.
The following steps in this project will confirm the small molecules as
potential treatments for DGUOK deficiency. Along with an increase in ATP
production, the most vital assay would be to measure mtDNA content in the
knockout cells with the hit compounds. Measuring mtDNA is crucial to finding
the cure to MTDPS3. There is a possibility that some or all the compounds will
affect the production of mtDNA. If so, then the mitochondria in those cells must
have the purine nucleotides needed to produce mtDNA; in this case, that would
explain the increased production in ATP because, as mentioned above, the
mitogenome codes for the ETC complexes. However, just like NAD, the
compounds could not positively influence mtDNA content, but there is a
possibility that they can.
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It is known that mtDNA needs a continuous supply of dNTPs for
mitochondria homeostasis (Almannai, El-Hattab, & Scaglia, 2018). This is
through specific nucleotide salvage pathways, including DGUOK and TK2 and
mitochondrial transport proteins (Copeland, 2008; Spinazzola, 2011). Cytosolic
nucleotides are also imported to the double-membraned organelle by two
primary enzymes: thymidine phosphorylase and ribonucleotide reductase (RNR)
(Spinazzola, 2011; Almannai, El-Hattab, & Scaglia, 2018; Thelander, 2007; ElHattab, Craigen, & Scagila, 2017). The MTDPS3 phenotype has a depletion in
purine ribonucleotides. Therefore, if the compounds could increase mtDNA
content, it would not interact with thymidine phosphorylase. RNR, however, has
been seen to supply all dNTPs to the mitochondria for mtDNA replication
(Thelander, 2007). The candidate compounds have successfully increased ATP
production in DGUOK -/- iPSC-derived hepatocytes, which could be due to the
rescue of mtDNA through RNR.
It will also be imperative to measure mitochondrial morphology and
membrane potential. The DGUOK mutation causes detrimental effects on
mitochondrial morphology. In similar studies, DGUOK -/- cells and tissue
samples have disruptions in the mitochondrial structure, the matrix, and cristae
formation (Dimmock, et al., 2008; Jing, et al., 2018). Along with mitochondrial
morphology disruption, there seems to be a consistent decrease in mitochondrial
membrane potential in the cells (Jing, et al., 2018). Membrane potential is the
product of chemiosmosis during oxidative phosphorylation; restoring it could
have effects on MTDPS3 pathophysiology as well. Hopefully, this project is just
the beginning of a revolutionary approach to treating mitochondrial depletion
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syndromes. In the future, once the mechanism of action is known, and the
compounds can successfully restore the cells to wild-type mitochondrial
functions, animal studies and ultimately clinical trials are the only stages away
from improving the lives of MTDPS3 patients.
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Additional Dose-Response Assays
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Figure 18. Dose Response Assay, D-15082
The first attempt of a dose-response assay using compound D-15082 was
unsuccessful. The positive control, TM, did not have the anticipated increased
ATP production response. This result was due to the constant freezing and
thawing of this chemical, and over time it lost some of its chemical properties
that increased ATP levels. Therefore, this data is unusable and undecipherable. It
was expected that the 5uM concentration would increase ATP production due to
its similarity to the concentration used in the primary screen. There is the
possibility that the DGUOK -/- iPSC-derived hepatocytes did not differentiate
properly, or there was unnoticeable cell death. This could be due to human error
or the cells being a higher passage number, resulting in spontaneous and
unexpected differentiation.
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Normalized Ratio Averages (N=8)
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Figure 19. Dose Response Assay, D-88920 Lower Concentrations
The second attempt of a dose-response assay using compound D-88920 was
unsuccessful. The positive control, TM, did not have the anticipated increased
ATP production response. This result was due to the constant freezing and
thawing of this chemical, and over time it lost some of its chemical properties
that increased ATP levels. Therefore, this data is unusable and undecipherable. It
was expected that the 5uM concentration would increase ATP production due to
its similarity to the concentration used in the primary screen. This could be due
to human error or the cells being a higher passage number, resulting in
spontaneous and unexpected differentiation.
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